![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Insmed Initiates HIV-Associated Lipodystrophy Trial With Somatokine
Insmed Initiates HIV-Associated Lipodystrophy Trial With Somatokine
Insmed has initiated a Phase II clinical trial examining the therapeutic benefit of treating HIV-Associated Lipodystrophy with SomatoKine, the company's proprietary once daily IGF-I therapy.
The Phase II clinical trial is an open-label study designed to evaluate the safety and efficacy of SomatoKine for 12 weeks in 12 subjects with HIV-associated lipodystrophy.
To qualify for inclusion in the study, patients must be between 18 and 65 years of age, have confirmed HIV-1 infection, fat accumulation (visceral adiposity) and evidence of insulin resistance. The primary goal of the study is to determine the effects of SomatoKine on visceral fat and insulin sensitivity.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct